AgomAb Therapeutics CEO buys 6,000 and 5,000 shares

Q: How many AGMB shares did CEO Tim Jasper Knotnerus purchase, and at what prices?

He purchased 6,000 common shares at $8.48 per share on October 5, 2026, and 5,000 at $8.70 per share on October 6, 2026. No Rule 10b5-1 plan is reported for the purchases.

Q: What does the AGMB Form 4 report about shares held by TJK Life Sciences B.V.?

It lists 34,394 common shares held by TJK Life Sciences B.V. Knotnerus exercises voting and dispositive power over those shares and disclaims beneficial ownership for Section 16 purposes except to the extent of any pecuniary interest.

The CEO exercises voting and dispositive power over 34,394 common shares held by TJK Life Sciences B.V.

Filing Impact

(Neutral)

Filing Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

AgomAb Therapeutics NV (AGMB) Chief Executive Officer and director Tim Jasper Knotnerus reported two direct purchases of common shares: 6,000 at $8.48 on October 5, 2026, and 5,000 at $8.70 on October 6, 2026. No Rule 10b5-1 plan is reported for the purchases.

The report also lists 34,394 common shares held by TJK Life Sciences B.V. Knotnerus exercises voting and dispositive power over those shares and disclaims beneficial ownership for Section 16 purposes except to the extent of any pecuniary interest. Each American Depositary Share currently represents one common share.

Insider Trade Summary

Net Buyer: 11,000 shares

Net Buy 3 txns

Insider Knotnerus Tim Jasper

Role Chief Executive Officer

Bought 11,000 shs ($94K)

Type	Security	Shares	Price	Value
Purchase	Common shares ^F1	5,000	$8.70	$44K
Purchase	Common shares ^F1	6,000	$8.48	$51K
holding	Common shares ^{F1, F2}	--	--	--

Holdings After Transaction: Common shares — 21,823 shares (Direct); Common shares — 34,394 shares (Indirect, By TJK Life Sciences B.V.)

Footnotes (2)

F1. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
F2. Shares held by TJK Life Sciences B.V. ("TJK Life Sciences"). The Reporting Person exercises voting and dispositive power over the shares held by TJK Life Sciences and disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Key Figures

Direct purchase: 6,000 common shares Purchase price: $8.48 per share Direct purchase: 5,000 common shares +2 more

5 metrics

Direct purchase 6,000 common shares October 5, 2026

Purchase price $8.48 per share October 5, 2026

Direct purchase 5,000 common shares October 6, 2026

Purchase price $8.70 per share October 6, 2026

Indirect holding 34,394 common shares Held by TJK Life Sciences B.V.

Key Terms

American Depositary Shares, voting and dispositive power, pecuniary interest, beneficial ownership

4 terms

American Depositary Shares financial

"may be represented by American Depositary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

voting and dispositive power regulatory

"exercises voting and dispositive power over the shares"

pecuniary interest financial

"except to the extent of his pecuniary interest therein, if any"

beneficial ownership regulatory

"disclaims beneficial ownership of such shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AGMB shares did CEO Tim Jasper Knotnerus purchase, and at what prices?

He purchased 6,000 common shares at $8.48 per share on October 5, 2026, and 5,000 at $8.70 per share on October 6, 2026. No Rule 10b5-1 plan is reported for the purchases.

What does the AGMB Form 4 report about shares held by TJK Life Sciences B.V.?

It lists 34,394 common shares held by TJK Life Sciences B.V. Knotnerus exercises voting and dispositive power over those shares and disclaims beneficial ownership for Section 16 purposes except to the extent of any pecuniary interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/07/2026 - 08:07 AM Accepted by SEC EDGAR 10/07/2026 - 08:06 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Knotnerus Tim Jasper

(Last)

(First)

(Middle)

C/O AGOMAB THERAPEUTICS NV

POSTHOFLEI 1/6 2600

(Street)

ANTWERPEN

00000

(City)

(State)

(Zip)

BELGIUM

(Country)

2. Issuer Name and Ticker or Trading Symbol
AgomAb Therapeutics NV [ AGMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common shares⁽¹⁾	10/05/2026		P		6,000	A	$8.48	16,823	D
Common shares⁽¹⁾	10/06/2026		P		5,000	A	$8.7	21,823	D
Common shares⁽¹⁾								34,394	I	By TJK Life Sciences B.V.⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

2. Shares held by TJK Life Sciences B.V. ("TJK Life Sciences"). The Reporting Person exercises voting and dispositive power over the shares held by TJK Life Sciences and disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

	Ellen Lefever, Attorney-in-fact	10/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR